Background : The optimal TRT dose/fraction for LD-SCLC remains debatable, and due to increasing number of population in Egypt and number of patients as well, so reducing the duration of radiation therapy is favored. This study was conducted using etoposide and cisplatin (EP) concurrently with accelerated hypofractionated TRT to evaluate the response and toxicity of this protocol in the treatment of patients with limited-disease small cell lung cancer (LD-SCLC). Patients and Methods : Thirty patients with previously untreated LD-SCLC were enrolled into this study between June 2012 and February 2015. All patients received etoposide 100 mg/m 2 days 1 to 3 and cisplatin 25 mg/m 2 days 1 to 3 with start of accelerated hypofractionated thoracic radiation therapy on first day of the second cycle of chemotherapy of 55 Gy, 2.5 Gy/fraction over 30 days. Chemotherapy was given 4 - 6 cycles. Prophylactic cranial irradiation 25 Gy/10 fractions w ere given for patient s who achieved complete remission. Results : The median age was 60 years; 28 patients (93%) were men. ECOG PS was 0 in 5 (17%) patients and 1 in 12 (40%) patients. Four (13%) patients achieved a complete response (CR), 17 (57%) patients achieved a partial response (PR), while 7 patients (23%) had progressive disease (PD), and the ORR was 90%. The median survival time was 26.4 months. The median PFS was 16.7 months. Among the hematologic toxicities neutropenia was the most prevalent toxicity and it was evident as grade 3 - 4 in 12 (40%) patients. Grade 3 - 4 Asthenia was the most prevalent nonhematological toxicity, in 12 (40%) patients; esophagitis occurred in 7 (23%) patients. No treatment-related deaths (due to sepsis or bleeding) were reported in the study. Conclusion : Using etoposide and cisplatin concurrently with accelerated hypofractionated thoracic radiation therapy for the treatment of patients with LD-SCLC showed an encouraging outcome and acceptable toxicity and warrants further research.
Warde, P. and Payne, D. (1992) Does Thoracic Irradiation Improve Survival and Local Control in Limited-Stage Small-Cell Carcinoma of the Lung? A Meta-Analysis. Journal of Clinical Oncology, 10, 890-895. https://doi.org/10.1200/JCO.1992.10.6.890
Pignon, J.P. and Arriagada, R. (1992) Role of Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: Quantitative Review Based on the Literature versus Meta-Analysis Based on Individual Data. Journal of Clinical Oncology, 10, 1819-1820. https://doi.org/10.1200/JCO.1992.10.11.1819
Kong, F.M., Lally, B.E., Chang, J.Y., et al. (2013) ACR Appropriateness Criteria. Radiation Therapy for Small-Cell Lung Cancer. American Journal of Clinical Oncology, 36, 206-213. https://doi.org/10.1097/COC.0b013e31827e5523
Turrisi, A.T., Kim, K., Blum, R., et al. (1999) Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide. The New England Journal of Medicine, 340, 265-271. https://doi.org/10.1056/NEJM199901283400403
Bogart, J.A., Herndon, J.E., Lyss, A.P., Lee, M.E., et al. (2004) 70 Gy thoracic Radiotherapy Is Feasible Concurrent with Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Analysis of Cancer and Leukemia Group B Study 39808. International Journal of Radiation Oncology, Biology, Physics, 59, 460-468. https://doi.org/10.1016/j.ijrobp.2003.10.021
Miller, A.A., Wang, X.F., Bogart, J.A., et al. (2007) Phase II Trial of Paclitaxel-Topotecan-Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002. International Journal of Radiation Oncology, Biology, Physics, 2, 645-651. https://doi.org/10.1097/JTO.0b013e318074bbf5
Kelley, M., Bogart, J., Hodgeson, L., et al. (2013) Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer, CALGB 30206. Journal of Thoracic Oncology, 8, 102-108. https://doi.org/10.1097/JTO.0b013e31827628e1
Salama, J.K., Hodgson, L., Pang, H., et al. (2013) A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy CALGB 30904. Journal of Thoracic Oncology, 8, 1043-1049. https://doi.org/10.1097/JTO.0b013e318293d8a4
Overgaard, J., Hansen, H.S., Specht, L., et al. (2003) Five Compared with Six Fractions Per Week of Conventional Radiotherapy of Squamous-Cell Carcinoma of Head and Neck: DAHANCA 6 and 7 Randomized Controlled Trial. Lancet, 362, 933-940. https://doi.org/10.1016/S0140-6736(03)14361-9
Bese, N.S., Hendry, J. and Jeremic, B. (2007) Effects of Prolongation of Overall Treatment Time Due to Unplanned Interruptions during Radiotherapy of Different Tumor Sites and Practical Methods for Compensation. International Journal of Radiation Oncology, Biology, Physics, 68, 654-661. https://doi.org/10.1016/j.ijrobp.2007.03.010
Schild, S.E., Bonner, J.A., Shanahan, T.G., et al. (2004) Long-Term Results of a Phase III Trial Comparing Once-Daily Radiotherapy with Twice-Daily Radiotherapy in Limited-Stage Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 59, 943-951. https://doi.org/10.1016/j.ijrobp.2004.01.055
De Ruysscher, D., Pijls-Johannesma, M., Bentzen, SM., et al. (2006) Time between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small Cell Lung Cancer. Journal of Clinical Oncology, 24, 1057-1063. https://doi.org/10.1200/JCO.2005.02.9793
Videtic, G.M., Fung, K., Tomiak, A.T., et al. (2001) Using Treatment Interruptions to Palliate the Toxicity from Concurrent Chemoradiation for Limited Small Cell Lung Cancer Decreases Survival and Disease Control. Lung Cancer, 33, 249-258. https://doi.org/10.1016/S0169-5002(00)00240-3
Xia, B., Chen, G.Y., Cai, X.W., et al. (2011) The Effect of Bioequivalent Radiation Dose on Survival of Patients with Limited-Stage Small-Cell Lung Cancer. Radiation Oncology, 6, Article No. 50. https://doi.org/10.1186/1748-717X-6-50
Schild, S.E., Bonner, J.A., Hillman, S., et al. (2007) Results of a Phase II Study of High-Dose Thoracic Radiation Therapy with Concurrent Cisplatin and Etoposide in Limited-Stage Small-Cell Lung Cancer (NCCTG 95-20-53). Journal of Clinical Oncology, 25, 3124-3129. https://doi.org/10.1200/JCO.2006.09.9606
Murray, N., Coy, P., Pater, J.L., Hodson, I., Arnold, A., Zee, B.C., Payne, D., Kostashuk, E.C., Evans, W.K. and Dixon, P. (1993) Importance of Timing for Thoracic Irradiation in the Combined Modality Treatment of Limited-Stage Small Cell Lung Cancer. The National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 11, 336-344. https://doi.org/10.1200/JCO.1993.11.2.336
Work, E., Nielsen. O.S., Bentzen, S.M., Fode, K. and Palshof, T. (1997) Randomized Study of Initial versus Late Chest Irradiation Combined with Chemotherapy in Limited Stage Small-Cell Lung Cancer. Aarhus Lung Cancer Group. Journal of Clinical Oncology, 15, 3030-3037. https://doi.org/10.1200/JCO.1997.15.9.3030
Videtic, G.M., Truong, P.T., Dar, A.R., Yu, E.W. and Stitt, L.W. (2003) Shifting from Hypofractionated to “Conventionally” Fractionated Thoracic Radiotherapy: A Single Institution’s 10-Year Experience in the Management of Limited-Stage Small-Cell Lung Cancer Using Concurrent Chemoradiation. International Journal of Radiation Oncology, Biology, Physics, 57, 709-716. https://doi.org/10.1016/S0360-3016(03)00635-7
Yee, D., Halperin, R., Hanson, J., et al. (2006) Phase I Study of Hypofractionated Dose-Escalated Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 65, 466-473. https://doi.org/10.1016/j.ijrobp.2005.12.013
World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva.
Oken, M.M., Creech, R.H., Tormey, D.C., et al. (1982) Toxicity and Response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649-655. https://doi.org/10.1097/00000421-198212000-00014
Byhardt, R.W., Martin, L. and Pajak, T.F. (1993) The Influence of Field size and Other Treatment Factors on Pulmonary Toxicity Following Hyperfractionated Irradiation for Inoperable Non-Small-Cell Lung Cancer (NSCLC)—Analysis of a Radiation Therapy Oncology Group (RTOG) Protocol. International Journal of Radiation Oncology, Biology, Physics, 27, 537-544. https://doi.org/10.1016/0360-3016(93)90377-8
Kaplan, E.L. and Meier, P. (1958) Non-Parametric Estimation from Incomplete Observation. Journal of the American Statistical Association, 53, 457-481. https://doi.org/10.1080/01621459.1958.10501452
Abdelwahab, S., Abdulla, H., Azmy, A., et al. (2009) Integration of Irinotecan and Cisplatin with Early Concurrent Conventional Radiotherapy for Limited-Disease SCLC (LD-SCLC). International Journal of Clinical Oncology, 14, 230-236. https://doi.org/10.1007/s10147-008-0842-7
Takada, M., Fukuoka, M., Kawahara, M., et al. (2002) Phase III Study of Concurrent versus Sequential Thoracic Radiotherapy in Combination with Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. Journal of Clinical Oncology, 20, 3054-3060. https://doi.org/10.1200/JCO.2002.12.071
Pijls-Johannesma, M., De Ruysscher, D., Vansteenkiste, J., Kester, A., Rutten, I. and Lambin, P. (2007) Timing of Chest Radiotherapy in Patients with Limited Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Cancer Treatment Reviews, 33, 461-473. https://doi.org/10.1016/j.ctrv.2007.03.002
Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S. and Felip, E. (2013) Small-cell Lung Cancer (SCLC): ESMO Clinical Practice Guide-lines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, vi99-vi105. https://doi.org/10.1093/annonc/mdt178
Socha, J., Guzowska, A., Tyc-Szczepaniak, D., Wierzchowski, M., Sprawka, A., Szczesna, A. and Kepka, L. (2015) Accelerated Hypofractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer: Comparison with the Results of Conventionally Fractionated Radiotherapy. JBUON, 20, 146-157.
De Ruysscher, D. and Vansteenkiste, J. (2000) Chest Radiotherapy in Limited-Stage Small Cell Lung Cancer: Facts, Questions, Prospects. Radiotherapy & Oncology, 55, 1-9. https://doi.org/10.1016/S0167-8140(00)00156-0
Zhang, J., Fan, M., Liu, D., Zhao, K.L., Wu, K.L., Zhao, W.X., Zhu, Z.F. and Fu, X.L. (2017) Hypo- or Conventionally Fractionated Radiotherapy Combined with Chemotherapy in Patients with Limited Stage Small Cell Lung Cancer. Radiation Oncology, 12, Article No. 51. https://doi.org/10.1186/s13014-017-0788-x
Gronberg, B.H., Halvorsen, T.O., Flotten, O., et al. (2016) Randomized Phase II Trial Comparing Twice Daily Hyperfractionated with Once Daily Hypofractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer. Acta Oncologica, 55, 591-597. https://doi.org/10.3109/0284186X.2015.1092584